Melbourne researchers are helping expand options for people with high cholesterol that puts them at risk of heart attack or stroke, including world-first drugs for potentially deadly conditions.

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

“This drug is a game-changer,” Prof Nicholls said. “Not only do we have an option for lowering an elusive form of cholesterol ...

The results show that long-term use of antihypertensive drugs, cholesterol-lowering drugs, diuretics and blood-thinning drugs ...

The results show that long-term use of antihypertensive drugs, cholesterol-lowering drugs, diuretics and blood-thinning drugs ...

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

Managing diabetes and high cholesterol often requires lifestyle changes, such as eating healthier, exercising, and sometimes ...